Urothelial Cancer of Renal Pelvis study: Gemcitabine
Official title Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
ClinicalTrials.gov ID: NCT04865939
What this study is testing
What is Gemcitabine (intravesical)?
An investigational intravesical chemotherapy being studied to prevent bladder recurrence after surgery for upper‑tract urothelial cancer. Gemcitabine is designed to interfere with DNA synthesis in rapidly dividing cancer cells.
Also referred to as Gemzar.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see which method, gemcitabine chemotherapy or sterile water irrigation, better prevents bladder cancer coming back after surgery.
- Who it's for
- Adults who have had surgery to remove upper‑tract urothelial cancer (in the kidney pelvis or ureter).
- What's involved
- Participants will receive either gemcitabine placed into the bladder during surgery or continuous sterile water irrigation, followed by regular check‑ups and tests to monitor for cancer recurrence.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Biopsy proven UTUC with plan for excisional surgery (distal ureterectomy or nephroureterectomy) with curative intent
- Age 18 - 90 years
- Life expectancy \> 1 year
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control
- Has not undergone a hysterectomy or bilateral oophorectomy; or
You likely can't join if
- Concurrent or prior diagnosis of bladder cancer with a disease-free interval of less than three years.
- Synchronous bilateral upper tract urothelial carcinoma (prior history of contralateral UTUC is permissible with a disease-free interval of more than...
- Plan for radical cystectomy.
- Small bladder capacity (\< 100 mL).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or other agents used in study.
See the full eligibility criteria
- Biopsy proven UTUC with plan for excisional surgery (distal ureterectomy or nephroureterectomy) with curative intent
- Age 18 - 90 years
- Life expectancy \> 1 year
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- Ability to understand and the willingness to sign a written informed consent.
- Concurrent or prior diagnosis of bladder cancer with a disease-free interval of less than three years.
- Synchronous bilateral upper tract urothelial carcinoma (prior history of contralateral UTUC is permissible with a disease-free interval of more than three years).
- Plan for radical cystectomy.
- Small bladder capacity (\< 100 mL).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or other agents used in study.
The study team makes the final eligibility decision.
Where it is enrolling
- Dallas, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Dallas, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.